Phase II, proof-of-concept randomized controlled trial to evaluate dental caries preventive effects of fluoridated bottle water

第二阶段,概念验证随机对照试验,评估氟化瓶装水的龋齿预防效果

基本信息

  • 批准号:
    10458235
  • 负责人:
  • 金额:
    $ 104.92万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-17 至 2026-09-16
  • 项目状态:
    未结题

项目摘要

Dental health benefits of fluoride in drinking water have never been tested in a randomized controlled trial (RCT). Instead, results from observational studies and a few non-randomized, community intervention studies were sufficient to justify addition of fluoride to many public water systems during the 20th century and to defend against fluoridation’s critics. However, growth in fluoridated public water systems has stalled, leaving 100 million Americans living in places that do not have fluoridated water and which probably never will. A related problem is that, nationwide, 15% of children do not drink tap water for reasons ranging from consumer preference to distrust of public water. One solution, capitalizing on consumers’ demand for bottled water, is to increase consumption of fluoridated bottled water. However, RCT evidence of dental health benefits of fluoridated bottled water will be essential if public health is to embrace it as a strategy to extend fluoridation. In the absence of a precedent, and in the face of uncertainty as to compliance and likely effect size of the intervention, a fully powered RCT is premature. We instead propose a phase II, proof-of-concept RCT to evaluate dental caries preventive effects of fluoridated bottled water in a community not served by water fluoridation. The primary recruitment population is ~470 babies born during a one-year period in Kinston, NC, the state’s community with the largest non-fluoridated public water system where caries prevalence exceeds the state average. In households where measured content of fluoride in tap water is <0.2 ppm, we will randomize 200 infant/family dyads in a 1:1 ratio to receive either fluoridated or non-fluoridated bottled water. The two types of commercially water in 5-gallon bottles will be relabeled to mask infants, families and researchers as to the fluoride content. For 3½ years after randomization, each household will be provided with water, dispensers and other supplies to encourage water consumption consistent with nutritional recommendations. Bottled water consumption will be monitored and fingernail clippings collected to provide a biomarker-measure of fluoride intake. A dental examination conducted when children are aged 48?3 months will measure caries experience using the index of decayed, missing and filled tooth surfaces (dmfs). Statistical analysis will compare mean dmfs between study-groups to generate effect size estimates and standard errors needed to calculate sample size requirement for a future, multi-site, Phase III RCT. The investigative team has a strong record of accomplishment in observational and interventional studies of dental caries in children, and is experienced in work needed to plan (during the UG3 phase) and conduct (during the 5-year UH3 phase) the study as required by PAR-18-547. Local, state and national stakeholders have expressed support for the proposed study, noting its potential to improve oral health in underserved communities. By applying the rigor of a placebo-controlled RCT design, the study will address a serious shortfall in the evidence that hampers the nation’s primary public health strategy for dental caries prevention.
在随机对照试验中,氟化物在饮用水中的牙齿健康益处从未进行过测试 (RCT)。相反,观察性研究和一些非随机,社区干预研究的结果 足以证明在20世纪为许多公共供水系统添加氟化物并捍卫 反对氟化的关键。但是,氟化的公共供水系统的增长已经停滞不前,剩下100 数百万的美国人居住在没有氟化水且可能永远不会的地方。一个相关 问题是,在全国范围内,有15%的儿童因消费者的原因不喝自来水 偏爱不信任公共水。利用消费者对瓶装水的需求的一种解决方案是 增加氟化瓶装水的消耗。但是,RCT证据证明了牙科健康益处 如果将公共卫生作为扩展氟化的策略,则必须将氟化的瓶装水作为一种必要。 缺乏先例,面对不确定性的依从性,可能的效果大小 干预,完全动力的RCT为时过早。相反,我们提出了II期,概念证明RCT 在不被水提供的社区中评估龋齿预防性的预防作用 氟化。主要招聘人口约为470个婴儿,在北卡罗来纳州金斯顿的一年中出生 该州的社区是最大的非氟化公共供水系统,该系统的患病率超过了 州平均水平。在自来水中测量的氟化物含量的家庭中,我们将 以1:1的比例随机将200个婴儿/家庭二元组随机,以接收氟化或非氟化瓶装水。 5加仑瓶中的两种商业水将被重新标记为面具婴儿,家庭和 研究人员关于氟化物含量。随机化3。2.5年,每个家庭都将被提供 水,分配器和其他供应,以鼓励与营养一致的水消耗量 建议。瓶装水消耗将受到监控,并收集指甲剪剪以提供 氟化物摄入的生物标志物。儿童48岁3个月时进行的牙科检查 将使用腐烂,缺失和填充的牙齿表面(DMF)的索引来测量龋齿体验。统计 分析将比较研究组之间的平均DMF,以产生效应大小估计和标准误差 需要计算未来多站点,III期RCT的样本量需求。调查团队有 在儿童牙齿携带牙齿的观察和介入研究中,有很强的成就记录 在计划(在UG3阶段)并进行(在5年UH3阶段)的工作中经验丰富 根据Par-18-547的要求进行研究。地方,州和国家利益相关者已表示支持 拟议的研究指出,其潜力可以改善服务不足的社区。通过应用严格 该研究是安慰剂对照的RCT设计,将解决严重的缺口,以抑制这种证据 国家预防龋齿的主要公共卫生战略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Gary Douglas Slade其他文献

Gary Douglas Slade的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Gary Douglas Slade', 18)}}的其他基金

Phase II, proof-of-concept randomized controlled trial to evaluate dental caries preventive effects of fluoridated bottle water
第二阶段,概念验证随机对照试验,评估氟化瓶装水的龋齿预防效果
  • 批准号:
    10472070
  • 财政年份:
    2021
  • 资助金额:
    $ 104.92万
  • 项目类别:
Is Periodontal Disease Involved in the Etiology of Non-Alcoholic Fatty Liver Disease
牙周病是否与非酒精性脂肪肝的病因有关
  • 批准号:
    9111407
  • 财政年份:
    2016
  • 资助金额:
    $ 104.92万
  • 项目类别:
Is Periodontal Disease Involved in the Etiology of Non-Alcoholic Fatty Liver Disease
牙周病是否与非酒精性脂肪肝的病因有关
  • 批准号:
    9233074
  • 财政年份:
    2016
  • 资助金额:
    $ 104.92万
  • 项目类别:
Effects of cumulative stress and change in pain regulation on risk of chronic TMD
累积压力和疼痛调节变化对慢性 TMD 风险的影响
  • 批准号:
    8440291
  • 财政年份:
    2012
  • 资助金额:
    $ 104.92万
  • 项目类别:
Effects of cumulative stress and change in pain regulation on risk of chronic TMD
累积压力和疼痛调节变化对慢性 TMD 风险的影响
  • 批准号:
    8282086
  • 财政年份:
    2012
  • 资助金额:
    $ 104.92万
  • 项目类别:
Planning for International Studies of Population Oral Health Determinants
人口口腔健康决定因素的国际研究规划
  • 批准号:
    7449834
  • 财政年份:
    2008
  • 资助金额:
    $ 104.92万
  • 项目类别:
Planning for International Studies of Population Oral Health Determinants
人口口腔健康决定因素的国际研究规划
  • 批准号:
    7643354
  • 财政年份:
    2008
  • 资助金额:
    $ 104.92万
  • 项目类别:
Etiology and Modeling Core
病因学和建模核心
  • 批准号:
    8457069
  • 财政年份:
    2004
  • 资助金额:
    $ 104.92万
  • 项目类别:
Etiology and Modeling Core
病因学和建模核心
  • 批准号:
    8274677
  • 财政年份:
    2004
  • 资助金额:
    $ 104.92万
  • 项目类别:
Etiology and Modeling Core
病因学和建模核心
  • 批准号:
    8425167
  • 财政年份:
    2004
  • 资助金额:
    $ 104.92万
  • 项目类别:

相似国自然基金

近红外聚集诱导磷光铂(II)配合物的构筑及性能调控
  • 批准号:
    22305070
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
基于Wnt通路探讨装载淫羊藿次苷II外泌体靶向骨髓间充质干细胞成骨分化抗骨质疏松治疗的机制研究
  • 批准号:
    82374164
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
生物炭表面结构属性对Fe(II)氧化诱导As(III)氧化截污的影响机制
  • 批准号:
    42307492
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
叶绿体蛋白SQE1调控水稻非光化学淬灭和光系统II损伤修复的分子机制研究
  • 批准号:
    32370260
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
KIF17介导肿瘤细胞MHC-II胞膜定位促进乳腺癌抗原提呈及免疫应答的机制研究
  • 批准号:
    82372781
  • 批准年份:
    2023
  • 资助金额:
    46 万元
  • 项目类别:
    面上项目

相似海外基金

Metformin as a novel, mechanistic treatment of fibromyalgia; a proof of concept RCT
二甲双胍作为纤维肌痛的新型机械治疗方法;
  • 批准号:
    10655834
  • 财政年份:
    2023
  • 资助金额:
    $ 104.92万
  • 项目类别:
Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122
靶向胶质母细胞瘤中的 T 细胞功能障碍:抗 TIGIT 抗体 AB154 与抗 PD1 抗体 AB122 联合的概念验证 0/I 期试验
  • 批准号:
    10346649
  • 财政年份:
    2022
  • 资助金额:
    $ 104.92万
  • 项目类别:
Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122
靶向胶质母细胞瘤中的 T 细胞功能障碍:抗 TIGIT 抗体 AB154 与抗 PD1 抗体 AB122 联合的概念验证 0/I 期试验
  • 批准号:
    10573141
  • 财政年份:
    2022
  • 资助金额:
    $ 104.92万
  • 项目类别:
Targeting Clostridioides difficile with microbiome-sparing, resistant-proof anti-toxins
使用保留微生物组、抗耐药性的抗毒素来靶向艰难梭菌
  • 批准号:
    10376809
  • 财政年份:
    2021
  • 资助金额:
    $ 104.92万
  • 项目类别:
Phase II, proof-of-concept randomized controlled trial to evaluate dental caries preventive effects of fluoridated bottle water
第二阶段,概念验证随机对照试验,评估氟化瓶装水的龋齿预防效果
  • 批准号:
    10472070
  • 财政年份:
    2021
  • 资助金额:
    $ 104.92万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了